Novonesis A/S

Novonesis A/S is a global biotechnology company formed in 2024 through the merger of Novozymes and Chr. Hansen, creating the world leader in industrial enzymes and microbial solutions. Headquartered in Lyngby, Denmark, the company holds nearly 50% market share in both industrial enzymes and microbial solutions markets. With over a century of combined heritage from its founding companies, Novonesis specializes in research, development, and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. The company operates across more than 30 research and development centers and 23 manufacturing sites globally, serving over 30 different industries including household care, food and beverages, bioenergy, agriculture and feed, technical applications, and pharmaceuticals. Novonesis leverages the transformational power of biology through its portfolio of enzymes, functional proteins, and microbes to create biosolutions that address humanity's biggest challenges. In 2024, the company achieved 8% organic sales growth with trailing twelve-month revenue of $4.36 billion and maintained a strong pro forma adjusted EBITDA margin of 36.1%. With approximately 10,000 employees worldwide, Novonesis continues to drive innovation in biotechnology, offering sustainable solutions that enable change across numerous sectors from circular plastics and bioenergy to animal health and nutrition. The company's name, derived from the Greek word 'genesis', represents 'a new beginning' based on the power of biology, reflecting its mission to transform industries through cutting-edge biosolutions.